JP2019508440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508440A5 JP2019508440A5 JP2018548076A JP2018548076A JP2019508440A5 JP 2019508440 A5 JP2019508440 A5 JP 2019508440A5 JP 2018548076 A JP2018548076 A JP 2018548076A JP 2018548076 A JP2018548076 A JP 2018548076A JP 2019508440 A5 JP2019508440 A5 JP 2019508440A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- therapeutic combination
- diamine
- cyclohexane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 51
- 230000001225 therapeutic effect Effects 0.000 claims 29
- ALHBJBCQLJZYON-ZQDZILKHSA-N iadademstat Chemical compound C1C[C@@H](N)CC[C@@H]1N[C@H]1[C@H](C=2C=CC=CC=2)C1 ALHBJBCQLJZYON-ZQDZILKHSA-N 0.000 claims 19
- 239000003112 inhibitor Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000001613 neoplastic effect Effects 0.000 claims 7
- 229940126161 DNA alkylating agent Drugs 0.000 claims 4
- 239000012624 DNA alkylating agent Substances 0.000 claims 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 4
- 239000012664 BCL-2-inhibitor Substances 0.000 claims 3
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims 3
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 3
- 102100039489 Histone-lysine N-methyltransferase, H3 lysine-79 specific Human genes 0.000 claims 3
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 3
- 101000963360 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 229940125763 bromodomain inhibitor Drugs 0.000 claims 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- 229940123877 Aurora kinase inhibitor Drugs 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- -1 verinostat Chemical compound 0.000 claims 2
- LXFOLMYKSYSZQS-XKHGBIBOSA-N (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-[[[3-[2-(6-tert-butyl-1H-benzimidazol-2-yl)ethyl]cyclobutyl]-propan-2-ylamino]methyl]oxolane-3,4-diol Chemical compound CC(C)(C)C1=CC=C2NC(CCC3CC(C3)N(C[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)C(C)C)=NC2=C1 LXFOLMYKSYSZQS-XKHGBIBOSA-N 0.000 claims 1
- FKSFKBQGSFSOSM-QFIPXVFZSA-N 1-[(2S)-butan-2-yl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-4-indolecarboxamide Chemical compound C1=C2N([C@@H](C)CC)C=C(C)C2=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C=C1C(C=N1)=CC=C1N1CCNCC1 FKSFKBQGSFSOSM-QFIPXVFZSA-N 0.000 claims 1
- LHGUZCKPFXXVPV-UHFFFAOYSA-N 1-[1-(1-ethylsulfonyl-4-piperidinyl)ethyl]-N-[(4-methoxy-6-methyl-2-oxo-1H-pyridin-3-yl)methyl]-2-methyl-3-indolecarboxamide Chemical compound C1CN(S(=O)(=O)CC)CCC1C(C)N1C2=CC=CC=C2C(C(=O)NCC=2C(NC(C)=CC=2OC)=O)=C1C LHGUZCKPFXXVPV-UHFFFAOYSA-N 0.000 claims 1
- WXRGFPHDRFQODR-ICLZECGLSA-N 1-[3-[[(2R,3S,4R,5R)-5-(4-amino-7-pyrrolo[2,3-d]pyrimidinyl)-3,4-dihydroxy-2-oxolanyl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea Chemical compound C([C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C2=NC=NC(N)=C2C=C1)O)N(C(C)C)CCCNC(=O)NC1=CC=C(C(C)(C)C)C=C1 WXRGFPHDRFQODR-ICLZECGLSA-N 0.000 claims 1
- IQCKJUKAQJINMK-HUBRGWSESA-N 1-[3-[[(2r,3s,4r,5r)-5-(4-amino-5-bromopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea Chemical compound C([C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C2=NC=NC(N)=C2C(Br)=C1)O)N(C(C)C)CCCNC(=O)NC1=CC=C(C(C)(C)C)C=C1 IQCKJUKAQJINMK-HUBRGWSESA-N 0.000 claims 1
- ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-6-[4-(4-morpholinylmethyl)phenyl]-4-indazolecarboxamide Chemical compound O=C1NC(C)=CC(C)=C1CNC(=O)C1=CC(C=2C=CC(CN3CCOCC3)=CC=2)=CC2=C1C=NN2C1CCCC1 ZOIBZSZLMJDVDQ-UHFFFAOYSA-N 0.000 claims 1
- FAWSUKOIROHXAP-NPMXOYFQSA-N 4-[(2s,4r)-1-acetyl-4-(4-chloroanilino)-2-methyl-3,4-dihydro-2h-quinolin-6-yl]benzoic acid Chemical compound N([C@@H]1C[C@@H](N(C2=CC=C(C=C21)C=1C=CC(=CC=1)C(O)=O)C(C)=O)C)C1=CC=C(Cl)C=C1 FAWSUKOIROHXAP-NPMXOYFQSA-N 0.000 claims 1
- ZLHFILGSQDJULK-UHFFFAOYSA-N 4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(NC=2N=C3C4=CC=C(Cl)C=C4C(=NCC3=CN=2)C=2C(=CC=CC=2F)OC)=C1 ZLHFILGSQDJULK-UHFFFAOYSA-N 0.000 claims 1
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims 1
- VUVUVNZRUGEAHB-CYBMUJFWSA-N 7-(3,5-dimethyl-4-isoxazolyl)-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-3H-imidazo[4,5-c]quinolin-2-one Chemical compound C1([C@@H](C)N2C3=C4C=C(C(=CC4=NC=C3NC2=O)C2=C(ON=C2C)C)OC)=CC=CC=N1 VUVUVNZRUGEAHB-CYBMUJFWSA-N 0.000 claims 1
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims 1
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- DNVXATUJJDPFDM-KRWDZBQOSA-N JQ1 Chemical compound N([C@@H](CC(=O)OC(C)(C)C)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 DNVXATUJJDPFDM-KRWDZBQOSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- QGZYDVAGYRLSKP-UHFFFAOYSA-N N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)-5-pyrimidinecarboxamide Chemical compound N1=CC(C(=O)NCCCCCCC(=O)NO)=CN=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 QGZYDVAGYRLSKP-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 229950000080 birabresib Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- QECMENZMDBOLDR-AWEZNQCLSA-N cpi 203 Chemical compound N([C@@H](CC(N)=O)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 QECMENZMDBOLDR-AWEZNQCLSA-N 0.000 claims 1
- VKIRRGRTJUUZHS-UHFFFAOYSA-N cyclohexane-1,4-diamine Chemical compound NC1CCC(N)CC1 VKIRRGRTJUUZHS-UHFFFAOYSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022159223A JP2023011569A (ja) | 2016-03-15 | 2022-10-03 | 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308529P | 2016-03-15 | 2016-03-15 | |
| US62/308,529 | 2016-03-15 | ||
| PCT/EP2017/055784 WO2017157825A1 (en) | 2016-03-15 | 2017-03-13 | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022159223A Division JP2023011569A (ja) | 2016-03-15 | 2022-10-03 | 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019508440A JP2019508440A (ja) | 2019-03-28 |
| JP2019508440A5 true JP2019508440A5 (enExample) | 2020-04-23 |
| JP7158023B2 JP7158023B2 (ja) | 2022-10-21 |
Family
ID=58266657
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548076A Active JP7158023B2 (ja) | 2016-03-15 | 2017-03-13 | 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ |
| JP2022159223A Pending JP2023011569A (ja) | 2016-03-15 | 2022-10-03 | 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022159223A Pending JP2023011569A (ja) | 2016-03-15 | 2022-10-03 | 固形腫瘍の治療における使用のための、ｌｓｄ１阻害剤の組合せ |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10265279B2 (enExample) |
| EP (1) | EP3429571B1 (enExample) |
| JP (2) | JP7158023B2 (enExample) |
| KR (2) | KR102511024B1 (enExample) |
| CN (2) | CN120661674A (enExample) |
| AR (1) | AR107871A1 (enExample) |
| AU (2) | AU2017233898B2 (enExample) |
| CA (1) | CA3017411C (enExample) |
| EA (1) | EA201892075A1 (enExample) |
| FI (1) | FI3429571T3 (enExample) |
| IL (1) | IL261721B (enExample) |
| MX (2) | MX381890B (enExample) |
| MY (1) | MY199967A (enExample) |
| SG (2) | SG11201807965YA (enExample) |
| WO (1) | WO2017157825A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013057320A1 (en) | 2011-10-20 | 2013-04-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| JP7082263B2 (ja) * | 2016-03-15 | 2022-06-08 | オリソン ヘノミクス エセ． アー． | 造血器悪性腫瘍の治療のための、ｌｓｄ１阻害剤の組合せ |
| WO2017157825A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| SI3307267T1 (sl) | 2016-06-10 | 2019-08-30 | Oryzon Genomics, S.A. | Zdravljenje multiple skleroze |
| US11685782B2 (en) | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
| MA50564A (fr) | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
| WO2019108789A1 (en) * | 2017-11-29 | 2019-06-06 | The Trustees Of Columbia University In The City Of New York | Combination therapy of lymphoma |
| BR112020021989A2 (pt) * | 2018-05-04 | 2021-01-26 | Oryzon Genomics, S.A. | formulação farmacêutica estável |
| MX2020011826A (es) | 2018-05-06 | 2021-01-15 | Ayala Pharmaceuticals Inc | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. |
| CN109265462B (zh) * | 2018-10-31 | 2020-06-02 | 郑州大学 | 嘧啶并1,2,4-三氮唑类化合物及其制备方法和应用 |
| CN113573702A (zh) * | 2019-03-25 | 2021-10-29 | 奥莱松基因组股份有限公司 | 用于癌症治疗的亚达司他的组合 |
| EP3994280A1 (en) * | 2019-07-05 | 2022-05-11 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
| CN110863047B (zh) * | 2019-11-15 | 2022-09-13 | 西安交通大学医学院第一附属医院 | 人ccdc154基因的用途及相关产品 |
| EP4682900A2 (en) * | 2020-01-28 | 2026-01-21 | PAIGE.AI, Inc. | Systems and methods for processing electronic images for biomarker localization |
| KR20220159405A (ko) * | 2020-03-17 | 2022-12-02 | 리제너론 파마슈티칼스 인코포레이티드 | 치료에 대한 반응자 결정 방법 및 시스템 |
| WO2021228146A1 (zh) * | 2020-05-12 | 2021-11-18 | 石药集团中奇制药技术（石家庄）有限公司 | 一种lsd1抑制剂的用途 |
| EP4419093A1 (en) | 2021-10-20 | 2024-08-28 | Queen Mary University of London | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
| GB202115017D0 (en) | 2021-10-20 | 2021-12-01 | Univ London Queen Mary | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
| CN118787751A (zh) * | 2023-04-12 | 2024-10-18 | 中国科学院上海药物研究所 | Lsd1抑制剂与药物联用治疗癌症的用途 |
| WO2025098488A1 (zh) * | 2023-11-09 | 2025-05-15 | 深圳艾欣达伟医药科技有限公司 | 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症 |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2802005A (en) | 1957-08-06 | S-eluorourace | ||
| US2331725A (en) | 1941-01-31 | 1943-10-12 | Lederle Lab Inc | Preparation of 2-methyl-1,4-naphthoquinone |
| US3205220A (en) | 1961-10-26 | 1965-09-07 | Lilly Co Eli | Leurosidine and leurocristine and their production |
| CH514578A (de) | 1968-02-27 | 1971-10-31 | Sandoz Ag | Verfahren zur Herstellung von Glucosiden |
| GB1457632A (en) | 1974-03-22 | 1976-12-08 | Farmaceutici Italia | Adriamycins |
| DD159877A1 (de) | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure |
| OA07174A (fr) | 1981-08-24 | 1984-04-30 | May & Baker Ltd | Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent. |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| ES8604088A1 (es) | 1985-06-14 | 1986-01-16 | Espanola Farma Therapeut | Procedimiento para la obtencion de un compuesto derivado de un acido dicarboxilico |
| FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5004758A (en) | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| IL96531A (en) | 1989-12-11 | 1995-08-31 | Univ Princeton | History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them) |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| EP0661284A1 (en) | 1992-09-18 | 1995-07-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
| TW438775B (en) | 1995-04-07 | 2001-06-07 | Pharmacia & Upjohn Co Llc | Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| JP3354090B2 (ja) | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| GB0108591D0 (en) | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| US7425553B2 (en) | 2003-05-30 | 2008-09-16 | Gemin X Pharmaceuticals Canada Inc. | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| AU2005225635B2 (en) | 2004-03-23 | 2010-06-24 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurodegenerative disorders |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| JP2008511548A (ja) | 2004-08-20 | 2008-04-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 抗アポトーシスｂｃｌ−２ファミリーメンバーの低分子阻害剤およびその使用法 |
| EP1789390B1 (en) | 2004-09-02 | 2011-11-09 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| WO2006071608A2 (en) | 2004-12-16 | 2006-07-06 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog lsd1 |
| DK1704859T3 (da) | 2005-02-18 | 2010-11-22 | Universitaetsklinikum Freiburg | Kontrol af androgen receptor-afhængig genenkspression ved inhibering af amin-oxidase-aktiviteten af lysin-specifik demetylase (LSD1) |
| JP5117374B2 (ja) | 2005-03-29 | 2013-01-16 | イコス・コーポレイション | Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体 |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| CN101175738B (zh) | 2005-05-12 | 2010-10-27 | 雅培制药有限公司 | 细胞凋亡促进剂 |
| WO2007015632A1 (en) | 2005-08-04 | 2007-02-08 | Cgk Co., Ltd. | Atm and atr inhibitor |
| KR20080088570A (ko) | 2005-08-10 | 2008-10-02 | 더 존스 홉킨스 유니버시티 | 항기생충 및 항암 치료제 및 라이신-특이적인 디메틸라제억제제로 유용한 폴리아민 |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| WO2008127734A2 (en) | 2007-04-13 | 2008-10-23 | The Johns Hopkins University | Lysine-specific demethylase inhibitors |
| CN101868446A (zh) | 2007-09-25 | 2010-10-20 | 托波塔吉特英国有限公司 | 某些异羟肟酸化合物的合成方法 |
| EP2307003A2 (en) * | 2008-05-16 | 2011-04-13 | Pharma Mar S.A. | Combination therapy with pm00104 and another antitumor agent |
| WO2010011845A2 (en) | 2008-07-24 | 2010-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods of preventing or treating viral infection or reactivation after latency in a host using inhibitors of the lsd1 protein |
| GEP20125592B (en) | 2008-09-17 | 2012-07-25 | Novartis Ag | Salts of n-[6-(cis-2,6-dimethylmorpholin-4-yl)- pyridine-3-yl]-2-methyl-4'- (trifluoromethoxy)[1,1'- biphenyl]-3-carboxamide |
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| JP5747025B2 (ja) | 2009-05-26 | 2015-07-08 | アッヴィ・バハマズ・リミテッド | 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤 |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2258865A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| WO2010143582A1 (ja) | 2009-06-11 | 2010-12-16 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びlsd1阻害剤 |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| US9708255B2 (en) | 2009-08-18 | 2017-07-18 | Robert A. Casero | (bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| BR112012006572A2 (pt) | 2009-09-25 | 2016-04-26 | Oryzon Genomics Sa | inibidores de demetilase-1 de lisina específicos e seu uso |
| US8946296B2 (en) | 2009-10-09 | 2015-02-03 | Oryzon Genomics S.A. | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| PT2526093T (pt) | 2010-01-22 | 2016-11-25 | Acetylon Pharmaceuticals Inc | Compostos amida reversa como inibidores de proteína desacetilase e métodos de utilização dos mesmos |
| WO2011106105A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| WO2011113005A2 (en) | 2010-03-12 | 2011-09-15 | The Johns Hopkins University | Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (dfmo) |
| WO2011131697A1 (en) | 2010-04-19 | 2011-10-27 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| PL2560949T3 (pl) | 2010-04-20 | 2017-01-31 | Università Degli Studi Di Roma "La Sapienza" | Pochodne tranylocyprominy jako inhibitory demetylazy histonowej LSD1 i/lub LSD2 |
| BR112012028556A2 (pt) | 2010-05-07 | 2014-04-01 | Glaxosmithkline Llc | Indóis |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| US20130252331A1 (en) | 2010-05-14 | 2013-09-26 | James Elliott Bradner | Compositions and methods for modulating metabolism |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| PL2598482T3 (pl) | 2010-07-29 | 2018-10-31 | Oryzon Genomics, S.A. | Inhibitory demetylazy lsd1 na bazie arylocyklopropyloaminy i ich zastosowanie medyczne |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| GB201112607D0 (en) | 2011-07-22 | 2011-09-07 | Glaxo Group Ltd | Novel compounds |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| DK2646444T3 (da) | 2010-12-03 | 2016-06-27 | Epizyme Inc | Substituerede purin- og 7-deazapurinforbindelser som modulatorer af epigenetiske enzymer |
| WO2012107499A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| EP2677865A4 (en) | 2011-02-23 | 2015-04-22 | Icahn School Med Mount Sinai | BROMODOMAIN INHIBITORS AS MODULATORS OF GENE EXPRESSION |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙（氟烷基）－１，４－苯二氮呯酮化合物 |
| JP5813855B2 (ja) | 2011-03-25 | 2015-11-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ | Ｌｓｄ１阻害剤としてのシクロプロピルアミン |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| US20140296255A1 (en) | 2011-05-19 | 2014-10-02 | Oryzong Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| JO3148B1 (ar) | 2011-07-27 | 2017-09-20 | Lilly Co Eli | مركب مثبط لإشارات مسار notch |
| EP2743256B1 (en) | 2011-08-09 | 2018-06-27 | Takeda Pharmaceutical Company Limited | Cyclopropaneamine compound |
| BR112014003382B1 (pt) | 2011-08-15 | 2022-03-15 | University Of Utah Research Foundation | Análogos de (e)-n-(1-feniletilideno) benzo-hidrazida substituída como inibidores de histona desmetilase e composições farmacêuticas compreendendo-os |
| SMT201900137T1 (it) * | 2011-10-20 | 2019-05-10 | Oryzon Genomics Sa | Composti di (etero)arile ciclopropilammina come inibitori di lsd1 |
| WO2013057320A1 (en) | 2011-10-20 | 2013-04-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| JP6138928B2 (ja) | 2012-06-01 | 2017-05-31 | ライプニッツ−インスティテュート フュア アルテルスフォルシュング−フリッツ−リップマン−インスティテュート エー．ファウ．（エフエルイー） | 医薬に使用されるｎｏｔｃｈシグナル伝達経路及び分泌の阻害物質 |
| CA2887598A1 (en) | 2012-10-12 | 2014-04-17 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
| US9388123B2 (en) | 2012-11-28 | 2016-07-12 | Kyoto University | LSD1-selective inhibitor having lysine structure |
| WO2014085613A1 (en) | 2012-11-30 | 2014-06-05 | Mccord Darlene E | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| CA2902225A1 (en) | 2013-02-28 | 2014-09-04 | Washington University | Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors |
| WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| EP2968343A4 (en) | 2013-03-14 | 2016-11-02 | Epizyme Inc | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
| EP3003301B1 (en) | 2013-05-30 | 2021-02-24 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells |
| AU2014281398B2 (en) | 2013-06-19 | 2018-10-04 | University Of Utah Research Foundation | Substituted (E)-N'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors |
| EP2829284A1 (en) * | 2013-07-22 | 2015-01-28 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor |
| AU2014306149B2 (en) | 2013-08-06 | 2019-09-19 | Imago Biosciences Inc. | KDM1A inhibitors for the treatment of disease |
| US9556170B2 (en) | 2013-08-30 | 2017-01-31 | University Of Utah Research Foundation | Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors |
| ES2863996T3 (es) * | 2013-12-06 | 2021-10-13 | Epizyme Inc | Terapia de combinación para el tratamiento del cáncer |
| LT3080100T (lt) | 2013-12-11 | 2023-02-27 | Celgene Quanticel Research, Inc. | Lizinui specifinės demetilazės-1 inhibitoriai |
| EP3102034A4 (en) | 2014-02-07 | 2017-07-12 | MUSC Foundation For Research Development | Aminotriazole- and aminotetrazole-based kdm1a inhibitors as epigenetic modulators |
| PH12020552066A1 (en) | 2014-02-13 | 2022-05-11 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| NZ723203A (en) | 2014-02-13 | 2020-08-28 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| US20170029366A1 (en) * | 2014-03-07 | 2017-02-02 | The Johns Hopkins University | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) |
| MX375990B (es) | 2014-04-11 | 2025-03-07 | Takeda Pharmaceuticals Co | Compuesto de ciclopropanamina y sus usos. |
| RS62874B1 (sr) | 2014-05-01 | 2022-02-28 | Celgene Quanticel Research Inc | Inhibitori lizin specifične demetilaze-1 |
| CA2953005C (en) | 2014-05-30 | 2023-03-14 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Cyclopropylamine compounds as histone demethylase inhibitors |
| CN106660987B (zh) | 2014-06-27 | 2020-11-06 | 赛尔基因昆蒂赛尔研究公司 | 赖氨酸特异性脱甲基酶-1的抑制剂 |
| ES2905280T3 (es) | 2014-07-03 | 2022-04-07 | Celgene Quanticel Res Inc | Inhibidores de la desmetilasa 1 específica de lisina |
| SMT202200136T1 (it) | 2014-07-03 | 2022-05-12 | Celgene Quanticel Research Inc | Inibitori della demetilasi lisina-specifica-1 |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| AU2015301746A1 (en) * | 2014-08-13 | 2017-02-16 | Celgene Corporation | Combination therapy for treating cancer |
| SG11201701683XA (en) | 2014-09-05 | 2017-04-27 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
| EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
| CN107438593B (zh) | 2015-01-30 | 2020-10-30 | 基因泰克公司 | 治疗化合物及其用途 |
| EP4559902A3 (en) | 2015-02-12 | 2025-08-20 | Imago Biosciences Inc. | Kdm1a inhibitors for the treatment of disease |
| CN106146361A (zh) | 2015-03-16 | 2016-11-23 | 四川大学 | 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途 |
| TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
| CN106045862B (zh) | 2015-04-10 | 2019-04-23 | 上海迪诺医药科技有限公司 | 环丙胺类螺(杂)环化合物、其药物组合物及应用 |
| US10526287B2 (en) | 2015-04-23 | 2020-01-07 | Constellation Pharmaceuticals, Inc. | LSD1 inhibitors and uses thereof |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| US20180284095A1 (en) | 2015-06-12 | 2018-10-04 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017004519A1 (en) | 2015-07-02 | 2017-01-05 | University Of Utah Research Foundation | Substituted benzohydrazide analogs as histone demethylase inhibitors |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| CN105233292B (zh) * | 2015-10-19 | 2018-03-13 | 中国科学院北京基因组研究所 | Ory‑1001联合放疗和化疗用于治疗人三阴性乳腺癌的用途 |
| CN105541806A (zh) | 2015-12-25 | 2016-05-04 | 中国药科大学 | 巴比妥酸类化合物、制备方法及其应用 |
| CN105924362B (zh) | 2016-02-05 | 2018-08-17 | 上海龙翔生物医药开发有限公司 | 芳香环丙基胺类化合物、其药学上可接受的盐、其制备方法及其用途 |
| JP7082263B2 (ja) | 2016-03-15 | 2022-06-08 | オリソン ヘノミクス エセ． アー． | 造血器悪性腫瘍の治療のための、ｌｓｄ１阻害剤の組合せ |
| WO2017157825A1 (en) * | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| CN106045881B (zh) | 2016-05-26 | 2017-10-31 | 新乡医学院 | 一类白藜芦醇衍生物、其制备方法及作为lsd1抑制剂的应用 |
-
2017
- 2017-03-13 WO PCT/EP2017/055784 patent/WO2017157825A1/en not_active Ceased
- 2017-03-13 IL IL261721A patent/IL261721B/en unknown
- 2017-03-13 JP JP2018548076A patent/JP7158023B2/ja active Active
- 2017-03-13 FI FIEP17710261.3T patent/FI3429571T3/fi active
- 2017-03-13 MX MX2018011102A patent/MX381890B/es unknown
- 2017-03-13 EP EP17710261.3A patent/EP3429571B1/en active Active
- 2017-03-13 CN CN202510879513.2A patent/CN120661674A/zh active Pending
- 2017-03-13 SG SG11201807965YA patent/SG11201807965YA/en unknown
- 2017-03-13 MY MYPI2018001572A patent/MY199967A/en unknown
- 2017-03-13 CA CA3017411A patent/CA3017411C/en active Active
- 2017-03-13 EA EA201892075A patent/EA201892075A1/ru unknown
- 2017-03-13 SG SG10201913331VA patent/SG10201913331VA/en unknown
- 2017-03-13 AU AU2017233898A patent/AU2017233898B2/en active Active
- 2017-03-13 KR KR1020187029530A patent/KR102511024B1/ko active Active
- 2017-03-13 CN CN201780029779.1A patent/CN109195593A/zh active Pending
- 2017-03-13 KR KR1020237008475A patent/KR20230042756A/ko not_active Ceased
- 2017-03-14 US US15/458,640 patent/US10265279B2/en active Active
- 2017-03-14 AR ARP170100628A patent/AR107871A1/es unknown
-
2018
- 2018-09-13 MX MX2021004639A patent/MX2021004639A/es unknown
-
2022
- 2022-05-04 US US17/661,971 patent/US20220378722A1/en active Pending
- 2022-10-03 JP JP2022159223A patent/JP2023011569A/ja active Pending
-
2023
- 2023-03-14 AU AU2023201580A patent/AU2023201580A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019508440A5 (enExample) | ||
| FI3429571T3 (fi) | Lsd1-inhibiittorien yhdistelmiä käytettäväksi kasvaintautien hoitamisessa | |
| CY1125292T1 (el) | Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2019510832A5 (enExample) | ||
| IL278297B2 (en) | Substituted heterocyclic inhibitors of ptpn11 | |
| WO2018218070A3 (en) | COVALENT INHIBITORS OF KRAS | |
| CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
| EA201891229A1 (ru) | Eif4a-ингибирующие соединения и связанные с ними способы | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| PH12020500327A1 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| CY1119356T1 (el) | Πυριδινυλ και συντηγμενα παραγωγα πυριδινυλ τριαζολονης | |
| JP2016528162A5 (enExample) | ||
| RU2016144668A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| WO2016080810A3 (ko) | 바이구아나이드 화합물 및 이의 용도 | |
| JP2015529234A5 (enExample) | ||
| JP2015512398A5 (enExample) | ||
| JP2014534269A5 (enExample) | ||
| TN2017000158A1 (en) | Carbazole derivatives | |
| JP2015502926A5 (enExample) | ||
| MY193740A (en) | "substituted 2,4 diamino-quinoline as new anticancer agents" | |
| MX394367B (es) | Moléculas tipo esfingolípidos sintéticas, fármacos, métodos de su síntesis y usos de los mismos. | |
| CR20160527A (es) | Derivados de carboxamida | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| RU2020102713A (ru) | Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата | |
| JP2016515550A5 (enExample) |